February 25, 2019
1 min read

Musician Peter Frampton reveals myositis diagnosis, farewell tour to fund research

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

During an interview on CBS Saturday Morning on Feb. 23, musician Peter Frampton revealed that he had been diagnosed with inclusion-body myositis, and announced the creation of the Peter Frampton Myositis Research Fund at the Johns Hopkins Myositis Center.

Frampton also noted in an interview with Rolling Stone that he plans to use $1 from every ticket sold on his farewell tour to fund the myositis center.

“Mr. Frampton’s candid interview with both CBS Saturday Morning and Rolling Stone magazine not only raises hope for those who live with myositis, but also brings awareness of this rare disease to the attention of the American public,” Mary McGowan, executive director of the nonprofit Myositis Association, told Healio Rheumatology. “By creating the Peter Frampton Myositis Research Fund at Johns Hopkins Myositis Center, he also raises awareness of the need for more research funding for IBM.”

Peter Frampton has revealed that he had been diagnosed with inclusion-body myositis.
Source: Carl Lender

Frampton began his music career as the lead singer and guitarist for the British band, The Herd. He later cofounded the band, Humble Pie, and would go on to collaborate with George Harrison, Harry Nilsson, David Bowie and Ringo Starr.

In his interview with Anthony Mason on CBS Saturday Morning, Frampton said he had been diagnosed with inclusion-body myositis 4 years ago, after noticing that his arms were growing weak. The Myositis Association responded, praising the musician for his “honesty in sharing his story with the public to help raise awareness and his message of inspiration and hope in the face of this progressive, disabling disease of the muscles.”

“TMA is the leading voice for myositis patients, their care partners, and family members, providing patient education and support, advocacy, physician education, and research funding,” McGowan said. “Since 2002, TMA has awarded more than $7 million in research funding for all myositis diseases in an effort to better understand these conditions, develop more effective therapies, and eventually to discover a cure.” – by Jason Laday